Is CHRS or CMPX more undervalued in 2026?

CirclFi compares Coherus Oncology, Inc. (CHRS) and Compass Therapeutics, Inc. (CMPX) using 13 institutional-grade valuation models. CHRS has a Quality of Company score of 6.8/10 while CMPX scores 5.3/10.

Which is a better buy — CHRS or CMPX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CHRS and CMPX valuations compare?

CHRS at $1.59 and CMPX at $2.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CHRS vs CMPX Valuation Comparison 2026 — Intrinsic Value Analysis

CHRS

Biological Products, (No Diagnostic Substances)

Coherus Oncology, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$1.59

Last close

Models

10/13

Active

CMPX

Biological Products, (No Diagnostic Substances)

Compass Therapeutics, Inc.

Quality

5.3

out of 10

Value Trap

LOW

Price

$2.38

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CHRS Fair Value	CHRS Upside	CMPX Fair Value	CMPX Upside
Bayesian DCF	Intrinsic	$0.53	-66.6%	$0.66	-72.5%
Earnings Power Value	Intrinsic	$9.90	+450.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.47	-73.6%	$0.18	-90.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CHRS vs CMPX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CHRS vs CMPX — Which Stock Is More Undervalued?

CHRS scores higher with a 6.8/10 quality rating vs CMPX's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Coherus Oncology, Inc. (CHRS) and Compass Therapeutics, Inc. (CMPX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CHRS currently trades at $1.59 with a QOC of 6.8/10, while CMPX trades at $2.38 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).